This trial will test the safety and effectiveness of a new type 2 diabetes medication vs. insulin glargine.
- Type 2 Diabetes
1 Primary · 9 Secondary · Reporting Duration: Week 52
Awards & Highlights
3 Treatment Groups
1 of 3
Insulin Efsitora Alfa
1 of 3
1 of 3
670 Total Participants · 3 Treatment Groups
Primary Treatment: Insulin Efsitora Alfa · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What site did they apply to?
|Clinvest Research LLC||50.0%|
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
- "Getting my blood under control and possibly getting paid"
How many prior treatments have patients received?
Frequently Asked Questions
Have any regulatory bodies granted authorization for LY3209590?
"Our team at Power rates the safety of LY3209590 a 3 on the scale due to this being a Phase 3 trial, with both evidence backing its efficacy and multiple verifications confirming its security." - Anonymous Online Contributor
How many distinct sites are overseeing this clinical trial?
"Syed Research Consultants Llc in Sheffield, AMCR Institute in Escondido and Velocity Clinical Research, Gardena in Gardena are just three of the 40 sites currently partaking in this medical study." - Anonymous Online Contributor
Are new participants currently being accepted for this research study?
"At present, clinicaltrials.gov signals that recruitment for this study has concluded. This trial was first posted on January 16th 2023 and last updated on December 21st 2022, however there are still 1474 other trials recruiting patients at the current moment in time." - Anonymous Online Contributor